Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study

被引:0
|
作者
Chen, Ruo-Yang [1 ]
Li, Da -Wei [1 ]
Wang, Jie-Ying [2 ]
Zhuang, Shao-Yong [1 ]
Wu, Hao-Yu [1 ]
Wu, Jia-Jin [1 ]
Qu, Jun-Wen [1 ]
Sun, Nan [1 ]
Zhong, Chen [1 ]
Zhu, Cheng [3 ]
Zhang, Ming [1 ,5 ]
Yu, Yue-Tian [4 ,5 ]
Yuan, Xiao-Dong [1 ,5 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Clin Res Ctr, Sch Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Dis Prevent & Control, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Crit Care Med, Shanghai, Peoples R China
[5] 145 Middle Shandong Rd, Shanghai, Peoples R China
关键词
Trimethoprim-sulfamethoxazole; Kidney transplantation; Pneumocystis jirovecii pneumonia; Fungal infection; Prophylaxis;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate the efficacy and safety of low-dose trimethoprim (TMP)-sulfamethoxazole (SMX) (TMP-SMX) as the primary prophylaxis for Pneumocystis jirovecii pneumonia (PJP) in adult recipients of kidney transplantation.Methods: Three kinds of prescriptions in kidney recipients were documented, including 20 mg TMP/100 mg SMX oral daily, 20 mg TMP/100 mg SMX oral every other day, and nonprophylaxis. The primary outcome was the incidence of PJP in the first 180 days of follow-up after kidney transplantation. The secondary outcomes were changes in renal and liver function.Results: Among the 1469 recipients, 1066 (72.56%) received 20 mg TMP/100 mg SMX daily, 127 (8.65%) received 20 mg TMP/100 mg SMX every other day, and 276 (18.79%) did not have prophylaxis prescrip-tion. The 276 recipients in the nonprophylaxis group had 124.92 person-years of follow-up, during which PJP occurred in 29 patients, for an incidence rate of 23.21 (95% confidence interval 15.76-32.72) per 100 person-years. The TMP-SMX daily group and the TMP-SMX every other day group had 524.89 and 62.07 person-years of follow-up, respectively, with no occurrence of PJP. There was no significant difference among the three groups in changes in renal and liver function ( P > 0.05, respectively). A total of 111 recipients in each group were enrolled in the propensity score matching analysis. It was revealed that the 111 nonprophylaxis recipients had 51.27 person-years of follow-up and 10 PJP cases. Prophylaxis was considered effective because there was a significant difference between the three groups ( P < 0.001).Conclusion: Low-dose TMP-SMX prophylaxis significantly reduces the incidence of PJP within 6 months after kidney transplantation and has a favorable safety profile.& COPY; 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:209 / 215
页数:7
相关论文
共 38 条
  • [21] LOW-DOSE INTERMITTENT TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    WORMSER, GP
    HOROWITZ, HW
    DUNCANSON, FP
    FORSETER, G
    JAVALY, K
    ALAMPUR, SK
    GILROY, SA
    LENOX, T
    RAPPAPORT, A
    NADELMAN, RB
    ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (04) : 688 - 692
  • [22] Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation
    Torre-Cisneros, J
    De la Mata, M
    Pozo, JC
    Serrano, P
    Briceño, J
    Solórzano, G
    Miño, G
    Pera, C
    Sánchez-Guijo, P
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (04) : 771 - 774
  • [23] A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection
    Kosaka, Makoto
    Ushiki, Atsuhito
    Ikuyama, Yuichi
    Hirai, Kazuya
    Matsuo, Akemi
    Hachiya, Tsutomu
    Hanaoka, Masayuki
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (12)
  • [24] Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study
    Kanae Yamashita
    Yoshimitsu Shimomura
    Hiroaki Ikesue
    Nobuyuki Muroi
    Akihiro Yoshimoto
    Tohru Hashida
    BMC Infectious Diseases, 21
  • [25] Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study
    Yamashita, Kanae
    Shimomura, Yoshimitsu
    Ikesue, Hiroaki
    Muroi, Nobuyuki
    Yoshimoto, Akihiro
    Hashida, Tohru
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [26] Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study
    Aggoun, Dahlia
    Verdonk, Constance
    Bleibtreu, Alexandre
    Fekkar, Arnaud
    Houze, Sandrine
    Zafrani, Lara
    Desire, Eva
    Varnous, Shaida
    Leprince, Pascal
    Coutance, Guillaume
    Lescroart, Mickael
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025,
  • [27] Impact of Very Low-Dose Trimethoprim-Sulfamethoxazole on Serum Creatinine after Renal Transplantation: A Retrospective Study
    Yamanaga, Shigeyoshi
    Tanaka, Kosuke
    Kinoshita, Kohei
    Kaba, Akari
    Fujii, Mika
    Ogata, Masatomo
    Hidaka, Yuji
    Kawabata, Chiaki
    Toyoda, Mariko
    Uekihara, Soichi
    Kashima, Masayuki
    Miyata, Akira
    Inadome, Akito
    Yokomizo, Hiroshi
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (06) : 1757 - 1761
  • [28] The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study
    Zhao, Yi-Chang
    Xiao, Chen-Lin
    Hou, Jing-Jing
    Li, Jia-Kai
    Zhang, Bi-Kui
    Xie, Xu-Biao
    Fang, Chun-Hua
    Peng, Feng-Hua
    Sandaradura, Indy
    Yan, Miao
    PHARMACEUTICS, 2022, 14 (12)
  • [29] Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort study
    Dina Creemers-Schild
    Frank P. Kroon
    Ed. J. Kuijper
    Mark G. J. de Boer
    Infection, 2016, 44 : 291 - 299
  • [30] USE OF LOW-DOSE TRIMETHOPRIM-SULFAMETHOXAZOLE THRICE WEEKLY FOR PRIMARY AND SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
    STEIN, DS
    STEVENS, RC
    TERRY, D
    LAIZURE, SC
    PALTE, S
    LANCASTER, DJ
    WEEMS, JJ
    WILLIAMS, CL
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) : 1705 - 1709